BioNTech SE
@BioNTech_Group
At #SGOAM26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer.
Read more: bit.ly/4voJn42
#BioNTech #WomensCancer #GynecologicOncology
Read more: bit.ly/4voJn42
#BioNTech #WomensCancer #GynecologicOncology
0 29